Form 4: Edwards Lifesciences CFO Scott B. Ullem Reports Stock Option Exercise and Share Sales

Scott B. Ullem, CFO of Edwards Lifesciences, exercised stock options and sold shares on February 28, 2025, according to a Form 4 filing with the SEC.

Summary

• On February 28, 2025, Scott B. Ullem, the Chief Financial Officer of Edwards Lifesciences Corp, exercised employee stock options to acquire 11,250 shares of common stock at a price of $45.2767 per share.
• Simultaneously, Ullem sold 3,490 shares at a weighted average price of $71.3819 and 7,760 shares at a weighted average price of $70.516.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2024.
• Following these transactions, Ullem directly owns 30,387 shares and indirectly owns 266,318 shares through a trust.
• He also directly owns 22,500 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned under a Rule 10b5-1 trading plan and do not necessarily reflect a change in the CFO's outlook on the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in financial analysis.
• Comparing Ullem's transactions to those of CFOs at comparable medical device companies like Medtronic or Abbott could provide context.
• However, without additional information, it's difficult to assess whether these transactions are typical or indicative of a specific trend.

Key Dates